Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients
Authors:
- P HiwarkarPHP Hiwarkar
- H B GasparHGH B Gaspar
- K GilmourKGK Gilmour
- M JaganiMJM Jagani
- R ChiesaRCR Chiesa
- N Bennett-ReesNBN Bennett-Rees
- J BreuerJBJ Breuer
- K RaoKRK Rao
- C CaleCCC Cale
- N GouldenNGN Goulden
- G DaviesGDG Davies
- P AmroliaPAP Amrolia
- 26 November 2012
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 48 (6) , 803-808
Abstract
While pre-emptive rituximab therapy for EBV has substantially reduced the incidence of post-transplant lymphoproliferative disorder, following allogeneic haematopoietic SCT (HSCT), cytomegalovirus (CMV) and adenovirus (ADV) still contribute to significant morbidity and mortality after HSCT. We therefore aimed to identify high-risk children who could benefit from recent advances in virus-specific immunotherapy, define the impact of viral reactivations on survival and estimate the economic burden of pre-emptive antiviral drug therapy. Between 2005 and 2010, prospective monitoring of 291 paediatric HSCT procedures revealed that reactivation of CMV (16%), ADV (15%) and EBV (11%) was frequent during period of CD4 T-cell lymphopenia (0.15 × 10(9) L(-1); P<0.05). We report significant risk factors for reactivation, most notably the use of serotherapy and development of GVHD (grade II) in the presence of pre-existing infection (ADV) or donor and/or recipient seropositivity (CMV, EBV). Most interestingly, CMV and ADV viraemia were the major independent predictors of mortality (P<0.05). CMV, ADV or EBV viral reactivation caused prolonged hospitalization (P<0.05), accounted for 15% of all mortality and substantially increased the cost of transplantation by ∼£22 500 ($34 000). This provides an economic rationale for targeting high-risk HSCT recipients with interventions such as virus-specific cell therapy.Keywords
This publication has 26 references indexed in Scilit:
- Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell TransplantationTransplantation, 2010
- Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?Transplantation Proceedings, 2004
- Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recoveryBlood, 2002
- High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionBlood, 2002
- The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantationBlood, 2001
- Adenovirus Infections in Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 1999
- Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experienceBone Marrow Transplantation, 1998
- Post-Transplant EBV Induced Lymphoproliferative DisordersLeukemia & Lymphoma, 1997
- Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignanciesBlood, 1991
- Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host diseaseBlood, 1986